Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases

Advanced Drug Delivery Reviews

Volumn 65, Issue 13-14, 2013, Pages 1816-1827

  Andrade, Fernanda ^a   Rafael, Diana ^b   Videira, Mafalda ^b   Ferreira, Domingos ^a   Sosnik, Alejandro ^c,d,e   Sarmento, Bruno ^f,g  

^a UNIVERSITY OF PORTO   (Portugal)

^b RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

^c UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^d Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^e TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^f UNIVERSITY INSTITUTE OF HEALTH SCIENCES IUCS   (Portugal)

^g INEB INSTITUTO DE ENGENHARIA BIOMÉDICA   (Portugal)

Author keywords

Drug resistance; Inhalation; Nanoparticles; Respiratory infections; Tuberculosis

Indexed keywords

DRUG RESISTANCE; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNODEFICIENCY SYNDROMES; INHALATION; PHARMACEUTICAL INDUSTRY; PULMONARY ADMINISTRATIONS; RESPIRATORY INFECTIONS; TUBERCULOSIS;

DRUG DELIVERY; NANOPARTICLES; NANOTECHNOLOGY;

DISEASES;

ALGINIC ACID; AMANTADINE; AMIKACIN; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CASPOFUNGIN; CHITOSAN; CIPROFLOXACIN; CYCLODEXTRIN; ETHAMBUTOL; ISONIAZID; ITRACONAZOLE; KANAMYCIN; LIPOSOME; MANNITOL; OSELTAMIVIR; PHOSPHATIDYLCHOLINE; POLYGLACTIN; POLYMYXIN B; PYRAZINAMIDE; RIFAMPICIN; RIMANTADINE; STREPTOMYCIN; TOBRAMYCIN; UNINDEXED DRUG; VORICONAZOLE; ZANAMIVIR;

ASPERGILLOSIS; BLASTOMYCOSIS; CANDIDIASIS; CARDIOTOXICITY; COCCIDIOIDOMYCOSIS; CRYPTOCOCCOSIS; DISEASE RESISTANCE; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG WITHDRAWAL; DRY POWDER INHALER; HISTOPLASMOSIS; HUMAN; INFLUENZA; INHALATIONAL DRUG ADMINISTRATION; LUNG INFECTION; MACROPHAGE; METERED DOSE INHALER; MYCOSIS; NANOTECHNOLOGY; NEBULIZER; NEPHROTOXICITY; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; SOUTH AMERICAN BLASTOMYCOSIS; SPOROTRICHOSIS; TUBERCULOSIS; VIRAL RESPIRATORY TRACT INFECTION;

AMB; AMPHOTERICIN B DEOXYCHOLATE; CDS; CYCLODEXTRINS; DDS; DISTEAROYLPHOSPHATIDYLCHOLINE; DPI; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE; DRY POWDER INHALERS; DSPC; EDTA; ETHYLENEDIAMINETETRAACETIC ACID; EXTENSIVELY DRUG-RESISTANT TB; GENERALLY RECOGNIZED AS SAFE; GRAS; INHALATION; MAC; MALEYLATED BOVINE SERUM ALBUMIN; MBSA; MDR-TB; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIC; MINIMUM INHIBITORY CONCENTRATION; MPEG-DSPE; MRSA; MULTIDRUG RESISTANT TB; MYCOBACTERIUM AVIUM-MYCOBACTERIUM INTRACELLULARE COMPLEX; NANO-DDS; NANOPARTICLES; NANOTECHNOLOGY-BASED DRUG DELIVERY SYSTEMS; NPS; O-PALMITOYL MANNAN; O-PALMITOYL PULLULAN; O-SAP; O-STEROYL AMYLOPECTIN; OPM; OPP; P-AMINOPHENYL-MANNOPYRANOSIDE; PAM; PC; PC:CHOL; PC:CHOL:DCP; PC:CHOL:P90; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLCHOLINE:CHOLESTEROL; PHOSPHATIDYLCHOLINE:CHOLESTEROL:DICETYLPHOSPHATE; PHOSPHATIDYLCHOLINE:CHOLESTEROL:P90; PLGA; PMDI; POLY(ETHYLENE OXIDE)-B-DISTEAROYL PHOSPHATIDYL-ETHANOLAMIN; POLY(LACTIDE-CO-GLYCOLIDE); PRESSURIZED METERED-DOSE INHALERS; RESPIRATORY INFECTIONS; SA-CSO; STEARIC ACID-GRAFTED CHITOSAN OLIGOSACCHARIDE; TB; TUBERCULOSIS; XDR-TB;

ADMINISTRATION, INHALATION; ANIMALS; ANTI-INFECTIVE AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG RESISTANCE, MICROBIAL; EQUIPMENT DESIGN; HUMANS; NANOPARTICLES; NANOTECHNOLOGY; NEBULIZERS AND VAPORIZERS; RESPIRATORY TRACT INFECTIONS;

EID: 84888198111     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2013.07.020     Document Type: Review

References (128)

1. Anderson P.J. History of aerosol therapy: liquid nebulization to MDIs to DPIs. Respir. Care 2005, 50:1139-1150.
2. Sanders M. Inhalation therapy: an historical review. Prim. Care Respir. J. 2007, 16:71-81.
3. Dessanges J.F. A history of nebulization. J. Aerosol Med. 2001, 14:65-71.
4. Knott F.A., Southwell N. Aerosol penicillin in the oxygen tent. Arch. Dis. Child. 1946, 21:16-18.
5. Humphrey J., Joules H. Penicillin inhalation in pulmonary disease. Lancet 1946, 2:221-225.
6. Southwell N. Inhaled penicillin in bronchial infections. Lancet 1946, 2:225-227.
7. Hurst A. Penicillin nebulization in bronchopulmonary disease: a preliminary report. Rocky Mt. Med. J. 1946, 43:219-221.
8. O'Riordan T. Inhaled antimicrobial therapy: from cystic fibrosis to the flu. Respir. Care 2000, 45:836-845.
9. McAllen M.K., Kochanowski S.J., Shaw K.M. Steroid aerosols in asthma: an assessment of betamethasone valerate and a 12-month study of patients on maintenance treatment. Br. Med. J. 1974, 1:171-175.
10. Muttil P., Wang C., Hickey A.J. Inhaled drug delivery for tuberculosis therapy. Pharm. Res. 2009, 26:2401-2416.
11. Geller D.E., Flume P.A., Staab D., Fischer R., Loutit J.S., Conrad D.J., f.t.M.S.Group Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. Am. J. Respir. Crit. Care Med. 2011, 183:1510-1516.
12. Bernstein D.I., Reuman P.D., Sherwood J.R., Young E.C., Schiff G.M. Ribavirin small-particle-aerosol treatment of influenza B virus infection. Antimicrob. Agents Chemother. 1988, 32:761-764.
13. Mohammad R.A., Klein K.C. Inhaled amphotericin B for prophylaxis against invasive Aspergillus infections. Ann. Pharmacother. 2006, 40:2148-2154.
14. Aitken M., Burke W., McDonald G., Shak S., Montgomery A., Smith A. Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis. A phase 1 study. JAMA 1992, 267:1947-1951.
15. Jones L.H., Baldock H., Bunnage M.E., Burrows J., Clarke N., Coghlan M., Entwistle D., Fairman D., Feeder N., Fulton C., Hilton L., James K., Jones R.M., Kenyon A.S., Marshall S., Newman S.D., Osborne R., Patel S., Selby M.D., Stuart E.F., Trevethick M.A., Wright K.N., Price D.A. Inhalation by design: dual pharmacology β-2 agonists/M3 antagonists for the treatment of COPD. Bioorg. Med. Chem. Lett. 2011, 21:2759-2763.
16. de Galan B., Simsek S., Tack C., Heine R. Efficacy and safety of inhaled insulin in the treatment of diabetes mellitus. Neth. J. Med. 2006, 64:319-325.
17. Huland E., Burger A., Fleischer J., Fornara P., Hatzmann E., Heidenreich A., Heinzer H., Heynemann H., Hoffmann L., Hofmann R., Huland H., Kampfer I., Kindler M., Kirchner H., Mehlhorn G., Moniak T.H., Rebmann U., Roigas J., Schneider T.H., Schnorr D., Schmitz H.J., Wenisch R., Varga Z., Vinke J. Efficacy and safety of inhaled recombinant interleukin-2 in high-risk renal cell cancer patients compared with systemic interleukin-2: an outcome study. Folia Biol. 2003, 49:183-190.
18. Videira M., Almeida A.J., Fabra A. Preclinical evaluation of a pulmonary delivered paclitaxel-loaded lipid nanocarrier antitumor effect. Nanomedicine 2012, 8(7):1208-1215.
19. Hokey D.A., Misra A. Aerosol vaccines for tuberculosis: a fine line between protection and pathology. Tuberculosis (Edinb.) 2011, 91:82-85.
20. Lu D., Garcia-Contreras L., Muttil P., Padilla D., Xu D., Liu J., Braunstein M., McMurray D.N., Hickey A.J. Pulmonary immunization using antigen 85-B polymeric microparticles to boost tuberculosis immunity. AAPS J. 2010, 12:338-347.
21. Roy I., Vij N. Nanodelivery in airway diseases: challenges and therapeutic applications. Nanomedicine 2010, 6:237-244.
22. Mansour H.M., Rhee Y.S., Wu X. Nanomedicine in pulmonary delivery. Int. J. Nanomedicine 2009, 4:299-319.
23. Bailey M., Berkland C. Nanoparticle formulations in pulmonary drug delivery. Med. Res. Rev. 2009, 29:196-212.
24. Smola M., Vandamme T., Sokolowski A. Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases. Int J Nanomedicine 2008, 3:1-19.
25. World Health Organization The top ten causes of death. The 10 leading causes of death by broad income group http://www.who.int/mediacentre/factsheets/fs310/en.
26. World Health Organization/The United Nations Children's Fund 2009, Global Action Plan for Prevention and Control of Pneumonia (GAPP).
27. Zumla A. Killer respiratory tract infections: time to turn the tide. Curr. Opin. Pulm. Med. 2012, 18:173-174.
28. Rello J., Diaz E. Pneumonia in the intensive care unit. Crit. Care Med. 2003, 31:2544-2551.
29. World Health Organization Global Tuberculosis Control: WHO Report 2012 2012.
30. Rastogi R., Sultana Y., Ali A., Aqil M. Particulate and vesicular drug carriers in the management of tuberculosis. Curr. Drug Deliv. 2006, 3:121-128.
31. Pinheiro M., Lúcio M., Lima J.L., Reis S. Liposomes as drug delivery systems for the treatment of TB. Nanomedicine (Lond.) 2011, 6:1413-1428.
32. Sosnik A., Carcaboso A.M., Glisoni R.J., Moretton M.A., Chiappetta D.A. New old challenges in tuberculosis: potentially effective nanotechnologies in drug delivery. Adv. Drug Deliv. Rev. 2010, 62:547-559.
33. Pandey R., Khuller G.K. Antitubercular inhaled therapy: opportunities, progress and challenges. J. Antimicrob. Chemother. 2005, 55:430-435.
34. Pimentel D., Videira M. Lipid nanocarriers as a strategy to promote phagocytosis and tropism for endocytic pathways in macrophages. 1st Post-Graduate iMed.UL Students Meeting 2009, Faculty of Pharmacy, University of Lisbon, Portugal.
35. Limper A.H., Knox K.S., Sarosi G.A., Ampel N.M., Bennett J.E., Catanzaro A., Davies S.F., Dismukes W.E., Hage C.A., Marr K.A., Mody C.H., Perfect J.R., Stevens D.A., A.T.S.F.W.Group An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am. J. Respir. Crit. Care Med. 2011, 183:96-128.
36. Laniado-Laborín R., Cabrales-Vargas M.N. Amphotericin B: side effects and toxicity. Rev. Iberoam. Micol. 2009, 26:223-227.
37. Vyas S.P., Quraishi S., Gupta S., Jaganathan K.S. Aerosolized liposome-based delivery of amphotericin B to alveolar macrophages. Int. J. Pharm. 2005, 296:12-25.
38. Gilani K., Moazeni E., Ramezanli T., Amini M., Fazeli M.R., Jamalifar H. Development of respirable nanomicelle carriers for delivery of amphotericin B by jet nebulization. J. Pharm. Sci. 2011, 100:252-259.
39. Agrawal A.K., Agrawal A., Pal A., Guru P.Y., Gupta C.M. Superior chemotherapeutic efficacy of amphotericin B in tuftsin-bearing liposomes against Leishmania donovani infection in hamsters. J. Drug Target. 2002, 10:41-45.
40. Jartti T., Jartti L., Ruuskanen O., Söderlund-Venermo M. New respiratory viral infections. Curr. Opin. Pulm. Med. 2012, 18:271-278.
41. Beckham J.D., Cadena A., Lin J., Piedra P.A., Glezen W.P., Greenberg S.B., Atmar R.L. Respiratory viral infections in patients with chronic, obstructive pulmonary disease. J. Infect. 2005, 50:322-330.
42. Rosenthal L.A., Avila P.C., Heymann P.W., Martin R.J., Miller E.K., Papadopoulos N.G., Peebles R.S., Gern J.E., E.a.O.R.D.I.S., Infections and Asthma Committee, American Academy of Allergy, Asthma & Immunology Viral respiratory tract infections and asthma: the course ahead. J. Allergy Clin. Immunol. 2010, 125:1212-1217.
43. World Health Oraganization Antimicrobial resistance http://www.who.int/mediacentre/factsheets/fs194/en/.
44. Centers for Disease Control and Prevention Antibiotic/antimicrobial resistance http://www.cdc.gov/drugresistance/index.html.
45. Zhang L., Pornpattananangku D., Hu C.M., Huang C.M. Development of nanoparticles for antimicrobial drug delivery. Curr. Med. Chem. 2010, 17:585-594.
46. Andrade F., Videira M., Ferreira D., Sarmento B. Micelle-based systems for pulmonary drug delivery and targeting. Drug Deliv. Lett. 2011, 1:171-185.
47. Bawarski W.E., Chidlowsky E., Bharali D.J., Mousa S.A. Emerging nanopharmaceuticals. Nanomedicine 2008, 4:273-282.
48. Duncan R., Gaspar R. Nanomedicine(s) under the microscope. Mol. Pharm. 2011, 8:2101-2141.
49. Bosetti R., Vereeck L. Future of nanomedicine: obstacles and remedies. Nanomedicine (Lond.) 2011, 6:747-755.
50. Hamburg M. FDA's approach to regulation of products of nanotechnology. Science 2012, 336:299-300.
51. U.S.Department of Health and Human Services, Food and Drug Administration Guidance for Industry: Considering Whether an FDA-Regulated Product Involves the Application of Nanotechnology 2011.
52. BCC Research Nanotechnology in medical applications: the global market (HLC069B) (accessed in March 2013). http://www.bccresearch.com/report/nanotechnology-medical-applications-global-market-hlc069b.html.
53. Andrade F., Videira M., Ferreira D., Sarmento B. Nanocarriers for pulmonary administration of peptides and therapeutic proteins. Nanomedicine (Lond.) 2011, 6:123-141.
54. Garcia-Contreras L., Fiegel J., Telko M.J., Elbert K., Hawi A., Thomas M., VerBerkmoes J., Germishuizen W.A., Fourie P.B., Hickey A.J., Edwards D. Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model. Antimicrob. Agents Chemother. 2007, 51:2830-2836.
55. Rytting E., Nguyen J., Wang X., Kissel T. Biodegradable polymeric nanocarriers for pulmonary drug delivery. Expert Opin. Drug Deliv. 2008, 5:629-639.
56. Pilcer G., Amighi K. Formulation strategy and use of excipients in pulmonary drug delivery. Int. J. Pharm. 2010, 392:1-19.
57. Oberdörster G., Oberdörster E., Oberdörster J. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ. Health Perspect. 2005, 113:823-839.
58. Carvalho T.C., Peters J.I., Williams R.O. Influence of particle size on regional lung deposition-what evidence is there?. Int. J. Pharm. 2011, 406:1-10.
59. Labiris N.R., Dolovich M.B. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br. J. Clin. Pharmacol. 2003, 56:588-599.
60. Telko M.J., Hickey A.J. Dry powder inhaler formulation. Respir. Care 2005, 50:1209-1227.
61. Dolovich M.B., Dhand R. Aerosol drug delivery: developments in device design and clinical use. Lancet 2011, 377:1032-1045.
62. Donovan M.J., Kim S.H., Raman V., Smyth H.D. Dry powder inhaler device influence on carrier particle performance. J. Pharm. Sci. 2012, 101:1097-1107.
63. Young P.M., Cocconi D., Colombo P., Bettini R., Price R., Steele D.F., Tobyn M.J. Characterization of a surface modified dry powder inhalation carrier prepared by "particle smoothing". J. Pharm. Pharmacol. 2002, 54:1339-1344.
64. U.S.Department of Health and Human Services Food and Drug Administration Guidance for Industry: Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients 2005.
65. ICH M3 (R2) Non-Clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals 2009.
66. ICH S3A Note for Guidance on Toxicokinetics: The Assessment of Systemic Exposure in Toxicity Studies 1994.
67. Zaru M., Mourtas S., Klepetsanis P., Fadda A.M., Antimisiaris S.G. Liposomes for drug delivery to the lungs by nebulization. Eur. J. Pharm. Biopharm. 2007, 67:655-666.
68. de Jesús Valle M.J., Dinis-Oliveira R.J., Carvalho F., Bastos M.L., Sánchez Navarro A. Toxicological evaluation of lactose and chitosan delivered by inhalation. J. Biomater. Sci. Polym. Ed. 2008, 19:387-397.
69. Grenha A., Grainger C., Dailey L., Seijo B., Martin G., Remuñán-López C., Forbes B. Chitosan nanoparticles are compatible with respiratory epithelial cells in vitro. Eur. J. Pharm. Sci. 2007, 31:73-84.
70. Mura S., Hillaireau H., Nicolas J., Le Droumaguet B., Gueutin C., Zanna S., Tsapis N., Fattal E. Influence of surface charge on the potential toxicity of PLGA nanoparticles towards Calu-3 cells. Int J Nanomedicine 2011, 6:2591-2605.
71. Davis M.E., Brewster M.E. Cyclodextrin-based pharmaceutics: past, present and future. Nat. Rev. Drug Discov. 2004, 3:1023-1035.
72. Bailey M.M., Gorman E.M., Munson E.J., Berkland C. Pure insulin nanoparticle agglomerates for pulmonary delivery. Langmuir 2008, 24:13614-13620.
73. Pilcer G., Vanderbist F., Amighi K. Spray-dried carrier-free dry powder tobramycin formulations with improved dispersion properties. J. Pharm. Sci. 2009, 98:1463-1475.
74. Labiris N.R., Dolovich M.B. Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br. J. Clin. Pharmacol. 2003, 56:600-612.
75. Alexander B.D., Winkler T.P., Shi S., Dodds Ashley E.S., Hickey A.J. In vitro characterization of nebulizer delivery of liposomal amphotericin B aerosols. Pharm. Dev. Technol. 2011, 16:577-582.
76. Heinemann L. The failure of exubera: are we beating a dead horse?. J. Diabetes Sci. Technol. 2008, 2:518-529.
77. Kriksunov L.B., Gumaste A.V. Inhaler 2008, Microdose Technologies Inc.
78. Crowder T.M. Highly reproducible powder aerosolisation for lung delivery using powder-specific electromechanical vibration. Expert Opin. Drug Deliv. 2005, 2:579-585.
79. Wakefield K., Genova P.A. Pneumatic Breath Actuated Inhaler 2001, IEP Pharmaceutical Devices Inc.
80. Pinto-Alphandary H., Andremont A., Couvreur P. Targeted delivery of antibiotics using liposomes and nanoparticles: research and applications. Int. J. Antimicrob. Agents 2000, 13:155-168.
81. Petersen E.A., Grayson J.B., Hersh E.M., Dorr R.T., Chiang S.M., Oka M., Proffitt R.T. Liposomal amikacin: improved treatment of Mycobacterium avium complex infection in the beige mouse model. J. Antimicrob. Chemother. 1996, 38:819-828.
82. Leitzke S., Bucke W., Borner K., Müller R., Hahn H., Ehlers S. Rationale for and efficacy of prolonged-interval treatment using liposome-encapsulated amikacin in experimental Mycobacterium avium infection. Antimicrob. Agents Chemother. 1998, 42:459-461.
83. Tomioka H., Saito H., Sato K., Yoneyama T. Therapeutic efficacy of liposome-encapsulated kanamycin against Mycobacterium intracellulare infection induced in mice. Am. Rev. Respir. Dis. 1991, 144:575-579.
84. Gangadharam P.R., Ashtekar D.R., Flasher D.L., Düzgüneş N. Therapy of Mycobacterium avium complex infections in beige mice with streptomycin encapsulated in sterically stabilized liposomes. Antimicrob. Agents Chemother. 1995, 39:725-730.
85. Vladimirsky M.A., Ladigina G.A. Antibacterial activity of liposome-entrapped streptomycin in mice infected with Mycobacterium tuberculosis. Biomed. Pharmacother. 1982, 36:375-377.
86. Swenson C.E., Popescu M.C., Ginsberg R.S. Preparation and use of liposomes in the treatment of microbial infections. Crit. Rev. Microbiol. 1988, 15(Suppl. 1):S1-S31.
87. Onyeji C.O., Nightingale C.H., Marangos M.N. Enhanced killing of methicillin-resistant Staphylococcus aureus in human macrophages by liposome-entrapped vancomycin and teicoplanin. Infection 1994, 22:338-342.
88. Dhillon J., Fielding R., Adler-Moore J., Goodall R.L., Mitchison D. The activity of low-clearance liposomal amikacin in experimental murine tuberculosis. J. Antimicrob. Chemother. 2001, 48:869-876.
89. Shaik N., Pan G., Elmquist W.F. Interactions of pluronic block copolymers on P-gp efflux activity: experience with HIV-1 protease inhibitors. J. Pharm. Sci. 2008, 97:5421-5433.
90. Suarez S., O'Hara P., Kazantseva M., Newcomer C.E., Hopfer R., McMurray D.N., Hickey A.J. Airways delivery of rifampicin microparticles for the treatment of tuberculosis. J. Antimicrob. Chemother. 2001, 48:431-434.
91. Suarez S., O'Hara P., Kazantseva M., Newcomer C.E., Hopfer R., McMurray D.N., Hickey A.J. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model. Pharm. Res. 2001, 18:1315-1319.
92. Hwang S.M., Kim D.D., Chung S.J., Shim C.K. Delivery of ofloxacin to the lung and alveolar macrophages via hyaluronan microspheres for the treatment of tuberculosis. J. Control Release 2008, 129:100-106.
93. Justo O.R., Moraes A.M. Incorporation of antibiotics in liposomes designed for tuberculosis therapy by inhalation. Drug Deliv. 2003, 10:201-207.
94. Abdulla J.M., Tan Y.T., Darwis Y. Rehydrated lyophilized rifampicin-loaded mPEG-DSPE formulations for nebulization. AAPS PharmSciTech 2010, 11:663-671.
95. Changsan N., Chan H.K., Separovic F., Srichana T. Physicochemical characterization and stability of rifampicin liposome dry powder formulations for inhalation. J. Pharm. Sci. 2009, 98:628-639.
96. Zaru M., Manca M.L., Fadda A.M., Antimisiaris S.G. Chitosan-coated liposomes for delivery to lungs by nebulisation. Colloids Surf. B Biointerfaces 2009, 71:88-95.
97. Zahoor A., Sharma S., Khuller G. Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. Int. J. Antimicrob. Agents 2005, 26:298-303.
98. Pandey R., Khuller G.K. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis (Edinb.) 2005, 85:227-234.
99. Pandey R., Sharma A., Zahoor A., Sharma S., Khuller G.K., Prasad B. Poly (dl-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J. Antimicrob. Chemother. 2003, 52:981-986.
100. Sharma A., Sharma S., Khuller G.K. Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. J. Antimicrob. Chemother. 2004, 54:761-766.
101. Justo O.R., Moraes A.M. Kanamycin incorporation in lipid vesicles prepared by ethanol injection designed for tuberculosis treatment. J. Pharm. Pharmacol. 2005, 57:23-30.
102. Desai T.R., Hancock R.E., Finlay W.H. Delivery of liposomes in dry powder form: aerodynamic dispersion properties. Eur. J. Pharm. Sci. 2003, 20:459-467.
103. Wong J.P., Yang H., Blasetti K.L., Schnell G., Conley J., Schofield L.N. Liposome delivery of ciprofloxacin against intracellular Francisella tularensis infection. J. Control Release 2003, 92:265-273.
104. Marier J.F., Brazier J.L., Lavigne J., Ducharme M.P. Liposomal tobramycin against pulmonary infections of Pseudomonas aeruginosa: a pharmacokinetic and efficacy study following single and multiple intratracheal administrations in rats. J. Antimicrob. Chemother. 2003, 52:247-252.
105. Marier J.F., Lavigne J., Ducharme M.P. Pharmacokinetics and efficacies of liposomal and conventional formulations of tobramycin after intratracheal administration in rats with pulmonary Burkholderia cepacia infection. Antimicrob. Agents Chemother. 2002, 46:3776-3781.
106. Omri A., Suntres Z.E., Shek P.N. Enhanced activity of liposomal polymyxin B against Pseudomonas aeruginosa in a rat model of lung infection. Biochem. Pharmacol. 2002, 64:1407-1413.
107. Alipour M., Halwani M., Omri A., Suntres Z.E. Antimicrobial effectiveness of liposomal polymyxin B against resistant Gram-negative bacterial strains. Int. J. Pharm. 2008, 355:293-298.
108. Hindi K.M., Ditto A.J., Panzner M.J., Medvetz D.A., Han D.S., Hovis C.E., Hilliard J.K., Taylor J.B., Yun Y.H., Cannon C.L., Youngs W.J. The antimicrobial efficacy of sustained release silver-carbene complex-loaded l-tyrosine polyphosphate nanoparticles: characterization, in vitro and in vivo studies. Biomaterials 2009, 30:3771-3779.
109. McConville J.T., Overhoff K.A., Sinswat P., Vaughn J.M., Frei B.L., Burgess D.S., Talbert R.L., Peters J.I., Johnston K.P., Williams R.O. Targeted high lung concentrations of itraconazole using nebulized dispersions in a murine model. Pharm. Res. 2006, 23:901-911.
110. Vaughn J.M., McConville J.T., Burgess D., Peters J.I., Johnston K.P., Talbert R.L., Williams R.O. Single dose and multiple dose studies of itraconazole nanoparticles. Eur. J. Pharm. Biopharm. 2006, 63:95-102.
111. Alvarez C.A., Wiederhold N.P., McConville J.T., Peters J.I., Najvar L.K., Graybill J.R., Coalson J.J., Talbert R.L., Burgess D.S., Bocanegra R., Johnston K.P., Williams R.O. Aerosolized nanostructured itraconazole as prophylaxis against invasive pulmonary aspergillosis. J. Infect. 2007, 55:68-74.
112. Hoeben B.J., Burgess D.S., McConville J.T., Najvar L.K., Talbert R.L., Peters J.I., Wiederhold N.P., Frei B.L., Graybill J.R., Bocanegra R., Overhoff K.A., Sinswat P., Johnston K.P., Williams R.O. In vivo efficacy of aerosolized nanostructured itraconazole formulations for prevention of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 2006, 50:1552-1554.
113. Vaughn J.M., Wiederhold N.P., McConville J.T., Coalson J.J., Talbert R.L., Burgess D.S., Johnston K.P., Williams R.O., Peters J.I. Murine airway histology and intracellular uptake of inhaled amorphous itraconazole. Int. J. Pharm. 2007, 338:219-224.
114. Yang W., Tam J., Miller D.A., Zhou J., McConville J.T., Johnston K.P., Williams R.O. High bioavailability from nebulized itraconazole nanoparticle dispersions with biocompatible stabilizers. Int. J. Pharm. 2008, 361:177-188.
115. Williams R.O., Zimmerer R.O., MxConville J.T., Tolman J.A., Wiederhold N.P., Peters J.I. Treatment of Pulmonary Fungal Infection with Voriconazole via Inhalation 2009, Board of Regents, The University of Texas System, CyDex Pharmaceuticals, Inc.
116. Ragle B.E., Karginov V.A., Bubeck Wardenburg J. Prevention and treatment of Staphylococcus aureus pneumonia with a beta-cyclodextrin derivative. Antimicrob. Agents Chemother. 2010, 54:298-304.
117. Vyas S.P., Kannan M.E., Jain S., Mishra V., Singh P. Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages. Int. J. Pharm. 2004, 269:37-49.
118. Ahsan F., Rivas I.P., Khan M.A., Torres Suarez A.I. Targeting to macrophages: role of physicochemical properties of particulate carriers-liposomes and microspheres-on the phagocytosis by macrophages. J. Control Release 2002, 79:29-40.
119. Chono S., Tanino T., Seki T., Morimoto K. Efficient drug targeting to rat alveolar macrophages by pulmonary administration of ciprofloxacin incorporated into mannosylated liposomes for treatment of respiratory intracellular parasitic infections. J. Control Release 2008, 127:50-58.
120. Vyas S.P., Khatri K. Liposome-based drug delivery to alveolar macrophages. Expert Opin. Drug Deliv. 2007, 4:95-99.
121. Moretton M.A., Chiappetta D.A., Andrade F.,Neves J., Ferreira D., Sarmento B., Sosnik A. Hydrolyzed galactomannan-modified nanoparticles and flower-like polymeric micelles for the active targeting of rifampicin to macrophages. J. Biomed. Nanotechnol. 2013, 9:1-12.
122. Zaru M., Sinico C., De Logu A., Caddeo C., Lai F., Manca M.L., Fadda A.M. Rifampicin-loaded liposomes for the passive targeting to alveolar macrophages: in vitro and in vivo evaluation. J. Liposome Res. 2009, 19:68-76.
123. Ohashi K., Kabasawa T., Ozeki T., Okada H. One-step preparation of rifampicin/poly(lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis. J. Control Release 2009, 135:19-24.
124. Gupta C.M., Haq W. Tuftsin-bearing liposomes as antibiotic carriers in treatment of macrophage infections. Methods Enzymol. 2005, 391:291-304.
125. Agarwal A., Kandpal H., Gupta H.P., Singh N.B., Gupta C.M. Tuftsin-bearing liposomes as rifampin vehicles in treatment of tuberculosis in mice. Antimicrob. Agents Chemother. 1994, 38:588-593.
126. Owais M., Ahmed I., Krishnakumar B., Jain R.K., Bachhawat B.K., Gupta C.M. Tuftsin-bearing liposomes as drug vehicles in the treatment of experimental aspergillosis. FEBS Lett. 1993, 326:56-58.
127. Sweeney L., Wang Z., Loebenberg R., Wong J., Lange C., Finlay W. Spray-freeze-dried liposomal ciprofloxacin powder for inhaled aerosol drug delivery. Int. J. Pharm. 2005, 305:180-185.
128. Tewes F., Brillault J., Couet W., Olivier J.C. Formulation of rifampicin-cyclodextrin complexes for lung nebulization. J. Control Release 2008, 129:93-99.